Zealand Pharma A/s
(NASDAQ) ZEAL
Zealand Pharma A/s Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$201.24M
Net Income (TTM)
$1.00B
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
ZEAL News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Zealand Pharma A/s
Industry
Biotechnology
Sector
Health CareEmployees
481
CEO
Adam Sinding Steensberg, MD, MBA
Website
www.zealandpharma.comHeadquarters
Copenhagen, 2860, DK
ZEAL Financials
Key Financial Metrics (TTM)
Gross Margin
100%
Operating Margin
76%
Net Income Margin
70%
Return on Equity
48%
Return on Capital
44%
Return on Assets
39%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$173.75M
Operating Income
$1.02B
EBITDA
$982.60M
Operating Cash Flow
$1.21B
Capital Expenditure
$22.13M
Free Cash Flow
$1.23B
Cash & ST Invst.
$1.43B
Total Debt
$787.43M
Zealand Pharma A/s Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$15.08M
-76.2%
Gross Profit
$12.16M
-65.3%
Gross Margin
80.69%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
237
N/A
Net Income
$181.04M
+52.4%
EBITDA
$191.93M
+45.5%
Quarterly Fundamentals
Net Cash
$333.04M
-67.9%
Accounts Receivable
$92.58M
+629.3%
Inventory
$3.76M
-91.8%
Long Term Debt
$776.98M
+616.4%
Short Term Debt
$13.22M
+16.0%
Return on Assets
39.21%
N/A
Return on Invested Capital
44.06%
N/A
Free Cash Flow
$320.75M
-17.6%
Operating Cash Flow
$317.01M
-14.4%